Candel Therapeutics, Inc.
About Candel Therapeutics, Inc.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2022
- $125.0K
- Net income
- -$38.2M
- Total assets
- $125.2M
- Market cap
- $623.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $48.3M
- Operating income
- -$48.3M
- Income tax
- $0
- Net income
- -$38.2M
- EPS (basic)
- $-0.72
- EPS (diluted)
- $-0.72
Balance sheet
- Total assets
- $125.2M
- Current assets
- $121.4M
- Total liabilities
- $73.3M
- Current liabilities
- $9.0M
- Shareholders’ equity
- $51.9M
Cash flow
- Operating cash flow
- -$38.3M
- Investing cash flow
- -$560.0K
- Financing cash flow
- $56.1M
- Net cash flow
- $17.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $623.5M
- EPS (diluted)
- $-0.72
- Shares outstanding
- 74.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 27, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $38.2M in FY2022.
- Trading 10% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Candel Therapeutics, Inc..
Write a review
News about Candel Therapeutics, Inc.
News & sentiment via Polygon.io
